Company intelligence / Profile preview

Clinical Laserthermia Systems

Ownership: Private
Development stage: Commercial

Overview

Clinical Laserthermia Systems has developed and commercialized the TRANBERG Thermal Therapy System for minimally invasive laser ablation of solid tumors. The system is CE marked in Europe and FDA 510(k) cleared for soft tissue ablation in the US. It is used clinically for focal therapy of prostate cancer and neurosurgical applications such as brain tumors and epileptic foci. Ongoing clinical studies are being conducted across several European countries to expand indications.

Therapeutic areas: OncologyNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

ClearPoint Neuro Inc. (for U.S. neurosurgical market distribution and co-development)

Beyond the preview

Go deeper on Clinical Laserthermia Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clinical Laserthermia Systems.

Explore the full profile